| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Revenue | ||||||
523 | 724 | 90 | ||||
Costs and expenses: | ||||||
Cost of revenue | ||||||
199 | 1,033 | 160 | ||||
Research and development | ||||||
25,670 | 22,353 | 16,551 | ||||
General and administrative | ||||||
6,669 | 4,619 | 4,483 | ||||
Total costs and expenses | ||||||
32,538 | 28,005 | 21,194 | ||||
Loss from operations | ||||||
-32,015 | -27,281 | -21,104 | ||||
Change in fair value of derivative liabilities | ||||||
- | 369 | 3,743 | ||||
Interest expense | ||||||
- | 392 | 1,358 | ||||
Loss on extinguishment of related party convertible promissory note | ||||||
- | -2,379 | - | ||||
Other income (expense), net | ||||||
152 | 165 | -40 | ||||
Loss before provision for income taxes | ||||||
-31,863 | -29,518 | -18,759 | ||||
Provision for income taxes | ||||||
0 | 0 | 0 | ||||
Net loss | ||||||
-31,863 | -29,518 | -18,759 | ||||
Net loss attributable to noncontrolling interests | ||||||
0 | 0 | -37 | ||||
Net loss attributable to Vaccinex, Inc. common stockholders | ||||||
-31,863 | -29,518 | -18,722 | ||||
Comprehensive loss | ||||||
-31,863 | -29,518 | - | ||||
Cumulative dividends on redeemable preferred stock | ||||||
- | - | -3,211 | ||||
Net loss attributable to Vaccinex, Inc. common stockholders, basic and diluted | ||||||
- | - | -21,933 | ||||
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted | ||||||
-2.47 | -5.65 | -19.90 | ||||
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted | ||||||
12,880 | 5,223 | 1,101 | ||||